A study by Kageyama et al., 2015, focused on targeted HLA-A*24:02-restricted MAGE-A4-expressing esophageal tumor cells in 10 patients via TCR-Ts without any lymphodepletion and showed an increased survival length of transferred TCR-Ts but with limited to no tumor regression [49]. Here, MAGEA4 is linked to neoplasm.